Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 10/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643025 | 0.81 | CCR5 (0.53) | CCR5SIGMAR1KCNA3OPRM1OPRL1 | |
| SCHEMBL7243378 | 0.81 | SIGMAR1 (0.72) | CCR5SIGMAR1KCNA3 | |
| SCHEMBL13929202 | 0.79 | CCR5 (0.50) | CCR5SIGMAR1KCNA3 | |
| SCHEMBL13929351 | 0.78 | L3MBTL1 (0.69) | CCR5SIGMAR1 | |
| SCHEMBL13929211 | 0.78 | SIGMAR1 (0.69) | CCR5SIGMAR1KCNA3 | |
| SCHEMBL13929209 | 0.78 | CCR5 (0.56) | CCR5SIGMAR1KCNA3 | |
| Benzene SCHEMBL8692613 | 0.78 | CCR5 (0.64) | CCR5KCNA3OPRM1OPRL1 | |
| SCHEMBL7247254 | 0.78 | KCNA3 (0.64) | CCR5SIGMAR1KCNA3OPRM1OPRL1 | |
| SCHEMBL13929339 | 0.78 | CCR5 (0.60) | CCR5SIGMAR1 | |
| SCHEMBL13929217 | 0.78 | CCR5 (0.63) | CCR5KCNA3OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173715-A2 | USE OF PIPERIDINE DERIVATIVES AS AGONISTS OF CHEMOKINE RECEPTOR ACTIVITY | Euroscreen S.A. (BE) | 2010-04-14 | — | — | EP | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009010478-A2 | USE OF PIPERIDINE DERIVATIVES AS AGONISTS OF CHEMOKINE RECEPTOR ACTIVITY | EUROSCREEN S.A. (BE) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | CCR5 2/4885SIGMAR1 129/4885KCNA3 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.